Ashton A - Search Results

1

Cellular radiosensitivity and complication risk after curative radiotherapy.

Peacock J, Ashton A, Bliss J, Bush C, Eady J, Jackson C, Owen R, Regan J, Yarnold J. Peacock J, et al. Among authors: ashton a. Radiother Oncol. 2000 May;55(2):173-8. doi: 10.1016/s0167-8140(00)00173-0. Radiother Oncol. 2000. PMID: 10799729

2

Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial.

Yarnold J, Ashton A, Bliss J, Homewood J, Harper C, Hanson J, Haviland J, Bentzen S, Owen R. Yarnold J, et al. Among authors: ashton a. Radiother Oncol. 2005 Apr;75(1):9-17. doi: 10.1016/j.radonc.2005.01.005. Epub 2005 Mar 16. Radiother Oncol. 2005. PMID: 15878095 Free article. Clinical Trial.

3

Heterozygosity for mutations in the ataxia telangiectasia gene is not a major cause of radiotherapy complications in breast cancer patients.

Shayeghi M, Seal S, Regan J, Collins N, Barfoot R, Rahman N, Ashton A, Moohan M, Wooster R, Owen R, Bliss JM, Stratton MR, Yarnold J. Shayeghi M, et al. Among authors: ashton a. Br J Cancer. 1998 Oct;78(7):922-7. doi: 10.1038/bjc.1998.602. Br J Cancer. 1998. PMID: 9764584 Free PMC article. Clinical Trial.

4

Ipsilateral breast tumor relapse: local recurrence versus new primary tumor and the effect of whole-breast radiotherapy on the rate of new primaries.

Gujral DM, Sumo G, Owen JR, Ashton A, Bliss JM, Haviland J, Yarnold JR. Gujral DM, et al. Among authors: ashton a. Int J Radiat Oncol Biol Phys. 2011 Jan 1;79(1):19-25. doi: 10.1016/j.ijrobp.2009.10.074. Epub 2010 May 13. Int J Radiat Oncol Biol Phys. 2011. PMID: 20471183

5

Evaluation of a method for grading late photographic change in breast appearance after radiotherapy for early breast cancer.

Haviland JS, Ashton A, Broad B, Gothard L, Owen JR, Tait D, Sydenham MA, Yarnold JR, Bliss JM. Haviland JS, et al. Among authors: ashton a. Clin Oncol (R Coll Radiol). 2008 Sep;20(7):497-501. doi: 10.1016/j.clon.2008.03.017. Epub 2008 May 27. Clin Oncol (R Coll Radiol). 2008. PMID: 18502105 Free article.

6

Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial.

Owen JR, Ashton A, Bliss JM, Homewood J, Harper C, Hanson J, Haviland J, Bentzen SM, Yarnold JR. Owen JR, et al. Among authors: ashton a. Lancet Oncol. 2006 Jun;7(6):467-71. doi: 10.1016/S1470-2045(06)70699-4. Lancet Oncol. 2006. PMID: 16750496 Free article. Clinical Trial.

7

Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial.

Ellis P, Barrett-Lee P, Johnson L, Cameron D, Wardley A, O'Reilly S, Verrill M, Smith I, Yarnold J, Coleman R, Earl H, Canney P, Twelves C, Poole C, Bloomfield D, Hopwood P, Johnston S, Dowsett M, Bartlett JM, Ellis I, Peckitt C, Hall E, Bliss JM; TACT Trial Management Group; TACT Trialists. Ellis P, et al. Lancet. 2009 May 16;373(9676):1681-92. doi: 10.1016/S0140-6736(09)60740-6. Lancet. 2009. PMID: 19447249 Free PMC article. Clinical Trial.

8

A phase II trial of induction chemotherapy followed by continuous hyperfractionated accelerated radiotherapy in locally advanced non-small-cell lung cancer.

Jenkins P, Anderson S, Wronski S, Ashton A. Jenkins P, et al. Among authors: ashton a. Radiother Oncol. 2009 Dec;93(3):396-401. doi: 10.1016/j.radonc.2009.04.002. Epub 2009 May 10. Radiother Oncol. 2009. PMID: 19435642 Clinical Trial.

9

Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial.

Muers MF, Stephens RJ, Fisher P, Darlison L, Higgs CM, Lowry E, Nicholson AG, O'Brien M, Peake M, Rudd R, Snee M, Steele J, Girling DJ, Nankivell M, Pugh C, Parmar MK; MS01 Trial Management Group. Muers MF, et al. Lancet. 2008 May 17;371(9625):1685-94. doi: 10.1016/S0140-6736(08)60727-8. Lancet. 2008. PMID: 18486741 Free PMC article. Clinical Trial.

10

ARC, an apoptosis suppressor limited to terminally differentiated cells, is induced in human breast cancer and confers chemo- and radiation-resistance.

Mercier I, Vuolo M, Madan R, Xue X, Levalley AJ, Ashton AW, Jasmin JF, Czaja MT, Lin EY, Armstrong RC, Pollard JW, Kitsis RN. Mercier I, et al. Among authors: ashton aw. Cell Death Differ. 2005 Jun;12(6):682-6. doi: 10.1038/sj.cdd.4401631. Cell Death Differ. 2005. PMID: 15861191 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

318 results

Search Page

Filters